Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a Positive Rating from Analysts?
Yahoo Finance · 2 weeks ago
Search results
At Teva Pharmaceuticals, we are all in for better health. We push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes for millions of patients every day.
- 16.40Add to watchlist-0.42 (-2.50%)At close:4:00 PM EDTFri. Jul 5, 202416.44 +0.04 (+0.24%)Pre mkt:6:36 AM EDTMon. Jul 8, 2024Delayed Quote (USD) · Pre-Market Time
- Open16.65High16.73Low16.32
- Mkt Cap18.87BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close16.8252 Wk. Low7.8052 Wk. High17.69
What analysts are sayingTop storiesRelated stocks
Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 18th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs.
Working together to help patients get the medicine they need. Our goal is to provide innovative treatments and quality generic and biosimilar medicines for millions of people. Learn more about Teva.
At Teva we believe that every one of us should have access to quality medicine that helps manage disease, fight infection, or simply improves overall health. Around 200 million people worldwide take one of our medicines every day.
Every day, Teva Pharmaceuticals helps around 200 million people around the world gain access to quality, affordable medicines. Our mission is to be a global leader in generics and biopharmaceuticals – and in doing so, ensuring a healthier tomorrow for our planet and for patients all around the world.
At Teva, we strive to deliver quality medicines to patients around the world with integrity and ethical business practices. What we do is important, but how we do it is just as important. Learn more: Working at Teva is more than a job; it helps millions of people enjoy healthier lives.
Jun 24, 2024 · Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza ®1 (liraglutide injection 1.8mg), in the United States.
